GMT Capital’s Sarepta Therapeutics SRPT Stock Holding History

GMT Capital’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-125,400	Closed	-$19.1M	–	91
2019 Q2	$19.1M	Buy	+125,400	New	+$15.2M	0.67%	33

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

GMT Capital's SRPT Position: Q3 2019 in Review

GMT Capital sold out of Sarepta Therapeutics (SRPT) in Q3 2019, closing a stake of 125,400 shares — an estimated $19.1M sold.

GMT Capital first reported a position in SRPT in Q2 2019 and held it in 1 quarter. The position peaked at $19.1M in Q2 2019. 340 funds tracked by Wall St. Rank hold SRPT as of Q3 2019.

GMT Capital reported no remaining Sarepta Therapeutics position as of Q3 2019 after selling out during the quarter.
GMT Capital sold 125,400 Sarepta Therapeutics shares in Q3 2019, an estimated $19.1M.
GMT Capital first reported a position in Sarepta Therapeutics in Q2 2019 and held it in 1 quarter.
GMT Capital's Sarepta Therapeutics position peaked at $19.1M in Q2 2019.
340 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2019.

Based on GMT Capital's 13F filing for Q3 2019, filed 13 Nov 2019.